Category Archives: Antibiotics

Man’s–And Clostridium difficile’s–Best Friend

This is disturbing (boldface mine; added line breaks for clarity): Nosocomial acquisition of Clostridium difficile is well documented, yet recent studies have highlighted the importance of community acquired infections and identified community associated reservoirs for this pathogen. Multiple studies have … Continue reading

Posted in Antibiotics, Public Health | 2 Comments

MCR-1 Confers Resistance To Lysozyme, Part Of Our Immune System

If you don’t know what pleiotropy means, you had better learn the word: when one mutational change confers multiple phenotypic effects. When it comes to antibiotic resistance, this is a bad thing–for us, anyway. Which brings us to mcr-1, the … Continue reading

Posted in Antibiotics, We're Really Fucked

It Sucks To Be This Patient: The Seven CPO Edition

It really does for this New Zealand (‘NZ’) patient (boldface mine): Here, we report the isolation of seven distinct CPO [carbapenemase producing organisms–resistant to the last line beta-lactam antibiotics], together with an ESBL-producing Pseudomonas aeruginosa and Proteus mirabilis with an … Continue reading

Posted in Antibiotics, KPC, NDM-1, Plasmids, Public Health, We're Really Fucked

Bacterial Whole Genome Sequencing And The Clinic: The Future Is Almost Here

I heard this talk almost a year ago*, so I’m glad this paper is finally out (I’ll translate into English below; boldface mine): The increasing prevalence of multidrug-resistant (MDR) bacteria is a serious global challenge. Here, we studied prospectively whether … Continue reading

Posted in Antibiotics, E. coli, Genomics, KPC, MRSA, NDM-1, Public Health | 1 Comment

Good News On The Antibiotic Development Front?

A while ago, I mentioned a serious problem in the attempt to combat drug resistance: …I think the greatest challenge is medicinal chemistry. By way of prelude, in days of yore, before the FDA approved virtually everything it was sent, … Continue reading

Posted in Antibiotics | 1 Comment

Five Percent of D.C.’s Enterobacterial Isolates Are CRE?

I’ve discussed before how difficult it is to measure the frequency of CRE (carbapenem-resistant enterobacteriaceae–E. coli and relatives that are usually resistant to all treatment, with the possible exception of colistin). This is, in part, due to a ‘denominator problem’: … Continue reading

Posted in Antibiotics, DC, KPC

Do Drug Companies Need Financial Incentives For Antibiotic Development?

One of the commonly stated problems that limits the development of new antibiotics is that the economic incentives are all wrong. A company has to spend a lot of money developing a drug that we then have an incentive not … Continue reading

Posted in Antibiotics | 3 Comments